Patents Represented by Attorney Steve Zelson
-
Patent number: 7094798Abstract: This invention relates to pyrrolocarbazole derivatives according formula I wherein R1, R2, R7, R8, R9, X and Y are as defined in the specification wherein said derivatives specifically inhibit one or both of the checkpoint kinases Wee1 and Chk1Type: GrantFiled: April 25, 2003Date of Patent: August 22, 2006Assignee: Pfizer IncInventors: Richard John Booth, Ellen Myra Dobrusin, Alan Kraker, Lorna Helen Mitchell, William Alexander Denny, Jeffrey Bruce Smaill, Andrew Mark Thompson, Florence Oliver Joseph McCarthy, Ho Huat Lee, Brian Desmond Palmer
-
Patent number: 7070976Abstract: The present invention provides genes encoding novel matrix metalloproteinases termed MMP; constructs and recombinant host cells incorporating the genes; the MMP polypeptides encoded by the genes; antibodies to the MMP polypeptides; and methods of making and using all of the foregoing.Type: GrantFiled: March 3, 2004Date of Patent: July 4, 2006Assignee: Pfizer Inc.Inventors: Timothy Wood, Jonas Ekblom, Erik Holmgren, Mats Kihlén
-
Patent number: 7067626Abstract: The present invention provides novel ion channel polypeptides and polynucleotides that identify and encode them. In addition, the invention provides expression vectors, host cells and methods for their production. The invention also provides methods for the identification of ion channel agonists/antagonists, useful for the treatment of human diseases and conditions.Type: GrantFiled: July 5, 2001Date of Patent: June 27, 2006Assignee: Pharmacia & Upjohn CompanyInventors: Christopher W. Benjamin, Steven L. Roberds, Alla M. Karnovsky, Cara L. Ruble
-
Patent number: 7045652Abstract: The invention relates to processes for preparing a compound of the formula (V) and alkyl boronic esters thereof wherein R1 is attached at the 2 or 3 position of the benzene ring, R2 is attached at the 5 or 6 position, and R1, R2 and G are as defined herein. Said compound is a key synthetic intermediate in the preparation of 2-amino-6-(substituted-4-phenoxy)-substituted-pyridines useful as nitric oxide synthase (NOS) inhibitors in a mammal.Type: GrantFiled: June 3, 2003Date of Patent: May 16, 2006Assignee: Pfizer INCInventors: Stephane Caron, Jolanta Nowakowski
-
Patent number: 7019147Abstract: The invention relates to compounds of formula (1) and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R1, R7, R8, R9, R10, and R11 are as defined herein. The invention also relates to methods of treating abnormal cell growth, such as cancer, in mammals by administering the compounds of formula 1 and to pharmaceutical compositions for treating such disorders which contain the compounds of formula (1). The invention also relates to methods of preparing the compounds of formula (1).Type: GrantFiled: November 10, 2000Date of Patent: March 28, 2006Assignee: Pfizer Inc.Inventors: Wayne E. Barth, Michael J. Luzzio, Joseph P. Lyssikatos
-
Patent number: 6207009Abstract: A process for producing paper or paperboard from mechanical pulp, in which the pulp is treated with a phenol-oxidizing enzyme after mechanical refining of the pulp has been completed. The resulting paper exhibits an increased strength relative to paper produced from untreated pulp.Type: GrantFiled: June 13, 1997Date of Patent: March 27, 2001Assignee: Novo Nordisk Biochem North America, Inc.Inventors: Tomas Tage Hansen, Peder Holk Nielsen
-
Patent number: 6184026Abstract: The present invention relates to methods of obtaining a mutant cell from a filamentous fungal parent cell, comprising: (a) obtaining mutant cells of the parent cell; (b) identifying the mutant cell which exhibits a more restricted colonial phenotype and/or a more extensive hyphal branching than the parent cell; and (c) identifying the mutant cell which has an improved property for production of a heterologous polypeptide than the parent cell, when the mutant and parent cells are cultured under the same conditions.Type: GrantFiled: September 24, 1999Date of Patent: February 6, 2001Assignee: Novo Nordisk Biotech, Inc.Inventors: Jeffrey R. Shuster, John C. Royer
-
Patent number: 6180366Abstract: The present invention relates to methods for producing a polypeptide, comprising: (a) cultivating a mutant of a parent filamentous fungal cell under conditions conducive for the production of the polypeptide, wherein (i) the mutant cell comprises a first nucleic acid sequence encoding the polypeptide and a second nucleic acid sequence comprising a modification of at least one of the genes involved in the production of a trichothecene and (ii) the mutant produces less of the trichothecene than the parent filamentous fungal cell when cultured under the same conditions; and (b) isolating the polypeptide from the cultivation medium. The present invention also relates to mutants of filamentous fungal cells and methods for obtaining the mutant cells. The present invention also relates to isolated trichodiene synthases and isolated nucleic acid sequences encoding the trichodiene synthases.Type: GrantFiled: May 20, 1999Date of Patent: January 30, 2001Assignee: Novo Nordisk Biotech, Inc.Inventors: John C. Royer, Lynne M. Christianson, Gregory A. Gambetta, Howard Brody, Suzanne M. Otani, Wendy T. Yoder
-
Patent number: 6146869Abstract: The present invention relates to isolated polypeptides having phospholipase B activity and isolated nucleic acid sequences encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing and using the polypeptides.Type: GrantFiled: October 21, 1999Date of Patent: November 14, 2000Assignee: Novo Nordisk Biotech, Inc.Inventors: Paul Harris, Kimberly M. Brown
-
Patent number: 6129769Abstract: The present invention relates to methods for dyeing a material, comprising (a) treating the material with a dyeing system which comprises one or more reduced vat dyes and/or one or more reduced sulfur dyes; and (b) oxidizing the one or more reduced vat dyes or one or more reduced sulfur dyes adsorbed onto the treated material with an oxidation system comprising (i) an oxygen source and one or more enzymes exhibiting oxidase activity or (ii) a hydrogen peroxide source and one or more enzymes exhibiting peroxidase activity, to convert the one or more reduced dyes to their original oxidized insoluble colored forms; wherein the material is a fabric, yarn, fiber, garment or film made of cotton, diacetate, flax, fur, hide, leather, linen, lyocel, polyacrylic, polyamide, polyester, ramie, rayon, silk, tencel, triacetate, viscose or wool.Type: GrantFiled: August 24, 1999Date of Patent: October 10, 2000Assignee: Novo Nordisk Biotech, Inc.Inventors: Feng Xu, Sonja Salmon, Heinz-Josef Wilhelm Deussen, Henrik Lund
-
Patent number: 6100057Abstract: The present invention relates to methods of producing hemoproteins comprising (a) introducing into a filamentous fungal cell, which is capable of producing the hemoprotein, (i) one or more first control sequences capable of directing the expression of a heme biosynthetic enzyme encoded by a first nucleic acid sequence endogenous to the filamentous fungal cell, wherein the one or more of the first control sequences are operably linked to the first nucleic acid sequence; and/or (ii) one or more copies of one or more second nucleic acid sequences encoding a heme biosynthetic enzyme; (b) cultivating the filamentous fungal cell in a nutrient medium suitable for production of the hemoprotein and the heme biosynthetic enzymes; and (c) recovering the hemoprotein from the nutrient medium of the filamentous fungal cell.Type: GrantFiled: June 9, 1997Date of Patent: August 8, 2000Assignee: Novo Nordisk Biotech, Inc.Inventors: Susan L. Elrod, Joel R. Cherry, Aubrey Jones
-
Patent number: 6090604Abstract: The present invention relates to isolated polypeptides having galactose oxidase activity and isolated nucleic acid sequences encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing and using the polypeptides.Type: GrantFiled: February 24, 1999Date of Patent: July 18, 2000Assignee: Novo Nordisk Biotech, Inc.Inventors: Elizabeth Golightly, Randy M. Berka, Michael W. Rey
-
Patent number: 6063607Abstract: The present invention relates to isolated polypeptides having choline oxidase activity and isolated nucleic acid sequences encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing and using the polypeptides.Type: GrantFiled: November 24, 1998Date of Patent: May 16, 2000Assignee: Novo Nordisk Biotech, Inc.Inventors: Debbie S. Yaver, Randy M. Berka, Michael W. Rey
-
Patent number: 6060305Abstract: The present invention relates non-toxic, non-toxigenic, non-pathogenic recombinant Fusarium host cells of the section Discolor or a teleomorph or synonym thereof, comprising a nucleic acid sequence encoding a heterologous protein operably linked to a promoter.Type: GrantFiled: March 13, 1997Date of Patent: May 9, 2000Assignee: Novo Nordisk Biotech, Inc.Inventors: John C. Royer, Donna L. Moyer, Yoder T. Wendy, Jeffrey R. Shuster
-
Patent number: 6060468Abstract: The present invention relates to novel N-substituted azaheterocyclic compounds of the general formula ##STR1## wherein X, Y, Z, R.sup.1, R.sup.1a, R.sup.2, R.sup.2a, p, r and s are as defined in the detailed part of the present description or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation as well as their use for treatment of indications caused by or related to secretion and circulation of insulin antagonising peptides.Type: GrantFiled: October 3, 1997Date of Patent: May 9, 2000Assignee: Novo Nordisk A/SInventors: Tine Krogh J.o slashed.rgensen, Erik Fischer, Rolf Hohlweg, Knud Erik Andersen, Uffe Bang Olsen, Zdenek Polivka, Vladimir Valenta, Karel Sindelar
-
Patent number: 6033892Abstract: The present invention relates to isolated polypeptides having 5-aminolevulinic acid synthase activity and isolated nucleic acid sequences encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing and using the polypeptides.Type: GrantFiled: November 16, 1998Date of Patent: March 7, 2000Assignee: Novo Nordis Biotech, Inc.Inventor: Greg Gambetta
-
Patent number: 6033891Abstract: The present invention relates to isolated nucleic acid sequences encoding polypeptides having cellobiose dehydrogenase activity. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as recombinant methods for producing the polypeptides.Type: GrantFiled: March 9, 1999Date of Patent: March 7, 2000Assignee: Novo Nordisk Biotech, Inc.Inventors: Elizabeth Golightly, Kimberly Brown
-
Patent number: 5348965Abstract: The invention relates to therapeutically active azaheterocyclic compounds and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating a central nervous system ailment related to the GABA uptake.Type: GrantFiled: May 14, 1992Date of Patent: September 20, 1994Assignee: Novo Nordisk A/SInventors: Knud E. Andersen, Lars J. S. Knutsen, Per O. Sorensen, Behrend F. Lundt, Jesper Lau, Hans Petersen